Sugi Predict

Sugi Predict / Compounds / SCHEMBL3396015

SCHEMBL3396015

SCHEMBL3396015

CC(=O)c1c(Cl)nc(N)nc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.43
▸ POLB P06746 1/20 0.41
▸ HSD17B10 Q99714 3/20 0.40
▸ TP53 P04637 1/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MAPK1 P28482 2/20 0.38
▸ LMNA P02545 2/20 0.36
▸ HPGD P15428 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ CASP7 P55210 1/20 0.36
▸ PABPC1 P11940 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA1 P30542 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27547854 0.87 KMT2A (0.39) KMT2APOLBHSD17B10TP53KDM4E
SCHEMBL6026297 0.84 KMT2A (0.36) KMT2APOLBHSD17B10TP53KDM4E
SCHEMBL7749289 0.82 SMN1; SMN2 (0.39) KMT2APOLBKDM4EALDH1A1SMN1; SMN2
SCHEMBL16507376 0.80 SMN1; SMN2 (0.42) KMT2APOLBHSD17B10TP53KDM4E
SCHEMBL27373968 0.77 POLB (0.52) KMT2APOLBHSD17B10KDM4EALDH1A1
SCHEMBL20067834 0.75 PPARG (0.41) KMT2APOLBKDM4EALDH1A1SMN1; SMN2
SCHEMBL9396189 0.75 NPSR1 (0.44) KMT2APOLBHSD17B10TP53KDM4E
Acetone SCHEMBL28276755 0.72 LMNA (0.52) HSD17B10TP53KDM4EALDH1A1SMN1; SMN2
SCHEMBL15817068 0.71 POLB (0.47) KMT2APOLBHSD17B10KDM4EALDH1A1
SCHEMBL8697727 0.70 ALDH1A1 (0.53) KMT2AHSD17B10TP53KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111018834-B Aminopyrimidine butenone derivatives as PPAR-gamma modulators 成都理工大学 2022-07-15 — — CN disclosed
CN-114667287-A Adenosine A2A receptor antagonists and uses thereof 泰昂治疗公司 2022-06-24 — — CN disclosed
EP-3999513-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF Teon Therapeutics, Inc. (US) 2022-05-25 — — EP disclosed
EP-3386984-B1 HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SRL (BE) 2021-08-11 — — EP disclosed
US-RE48622-E1 Therapeutically active pyrazolo-pyrimidine derivatives UCB Biopharma SRL (BE) 2021-07-06 — — US disclosed
WO-2021011670-A1 ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF TEON THERAPEUTICS, INC. (US) 2021-01-21 — — WO disclosed
US-10450320-B2 Hexahydropyrazinotriazinone derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BE) 2019-10-22 — — US disclosed
US-20180362532-A1 Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2018-12-20 — — US disclosed
EP-3386984-A1 HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2018-10-17 — — EP disclosed
EP-2935269-B1 THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES UCB BIOPHARMA SPRL (BE) 2018-04-11 — — EP disclosed
WO-2014096423-A1 THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES UCB PHARMA S.A. (BE) 2014-06-26 — — WO disclosed
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 — — EP disclosed
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 — — EP disclosed
US-20070111996-A1 Pyrazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2007-05-17 — — US disclosed
US-20070111996-A1 Pyrazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2007-05-17 — — US disclosed
US-20070111996-A1 Pyrazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2007-05-17 — — US disclosed
US-7148228-B2 Pyrazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2006-12-12 — — US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 — — EP disclosed
US-20050119282-A1 Pyrazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION 2005-06-02 — — US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119282-A1 Pyrazolopyrimidines and related analogs as HSP90-inhibitors HSP90AB2P, HSP90AB1, HSP90AA1 KMT2A 4161/4885POLB 1150/4885HSD17B10 2207/4885
US-10450320-B2 Hexahydropyrazinotriazinone derivatives as kinase inhibitors PI4KA, PI4KB, PI4K2B KMT2A 1323/4885POLB 1951/4885HSD17B10 1525/4885
US-20180362532-A1 Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors PI4KA, PI4KB, PI4K2B KMT2A 1323/4885POLB 1951/4885HSD17B10 1525/4885
US-20070111996-A1 Pyrazolopyrimidines and related analogs as HSP90-inhibitors HSP90AB2P, HSP90AB1, HSP90AA1 KMT2A 4161/4885POLB 1150/4885HSD17B10 2207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.